Compounds > 5-(pentadeca-8,11,14-trien-1-yl)resorcinol
Page last updated: 2024-11-12

5-(pentadeca-8,11,14-trien-1-yl)resorcinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-(pentadeca-8,11,14-trien-1-yl)resorcinol : A resorcinol compound having an 8-cis,11-cis-pentadeca-8,11,14-trien-1-yl substituent at the 5-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13259919
CHEMBL ID459603
CHEBI ID52680
SCHEMBL ID2467234

Synonyms (28)

Synonym
1,3-benzenediol, 5-(8z,11z)-8,11,14-pentadecatrienyl-
MEGXP0_000811
ACON1_000596
NCGC00168928-01
5-pentadecatrienyl resorcinol
BRD-K89787085-001-01-7
CHEBI:52680 ,
5-[(8z,11z)-pentadeca-8,11,14-trien-1-yl]benzene-1,3-diol
5-(8z,11z,14-pentadecatrienyl)resorcinol
79473-24-8
5-(pentadeca-8,11,14-trien-1-yl)resorcinol
(8z,11z)-5-(pentadeca-8,11,14-trien-1-yl)resorcinol
cardol triene
cardol 8'z,11'z,14'-triene
CHEMBL459603 ,
5-{8(z),11(z),14-pentadecatrienyl}resorcinol
bdbm50292425
1,3-benzenediol,5-(8z,11z)-8,11,14-pentadecatrien-1-yl-
SCHEMBL2467234
5-((8z,11z)-pentadeca-8,11,14-trien-1-yl)resorcinol
LMPK15030022
5-((8z,11z)-pentadeca-8,11,14-trien-1-yl)benzene-1,3-diol
DTXSID30872873
5-[(8z,11z)-pentadeca-8,11,14-trienyl]benzene-1,3-diol
NCGC00168928-02
Q27123547
1,3-benzenediol,5-(8z,11z)-8,11,14-pentadecatrienyl-
AKOS040754814

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
5-alkatrienylresorcinolA resorcinol compound having an alkatrienyl substituent at the 5-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
sorgoleone biosynthesis517

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1172565Toxicity in mouse B16F10 cells assessed as cell viability at 25.5 uM incubated for 72 hrs by BCA protein assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of dihydroresveratrol glycosides and evaluation of their activity against melanogenesis in B16F0 melanoma cells.
AID332456Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA1994Journal of natural products, Apr, Volume: 57, Issue:4
Tyrosinase inhibitors from Anacardium occidentale fruits.
AID1172561Inhibition of melanogenesis in mouse B16F10 cells assessed as reduction in melanin level at 25.5 uM incubated for 72 hrs2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of dihydroresveratrol glycosides and evaluation of their activity against melanogenesis in B16F0 melanoma cells.
AID1172564Toxicity in mouse B16F10 cells assessed as protein content at 25.5 uM incubated for 72 hrs by BCA protein assay2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of dihydroresveratrol glycosides and evaluation of their activity against melanogenesis in B16F0 melanoma cells.
AID1172563Potency index, ratio of kojic acid to test compound for inhibition of of melanogenesis in mouse B16F10 cells2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of dihydroresveratrol glycosides and evaluation of their activity against melanogenesis in B16F0 melanoma cells.
AID1172560Inhibition of melanogenesis in mouse B16F10 cells assessed as reduction in melanin level at 3.2 to 25.5 uM incubated for 72 hrs2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of dihydroresveratrol glycosides and evaluation of their activity against melanogenesis in B16F0 melanoma cells.
AID332455Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA at 0.8 mM1994Journal of natural products, Apr, Volume: 57, Issue:4
Tyrosinase inhibitors from Anacardium occidentale fruits.
AID332457Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA by Lineweaver-Burke plot analysis1994Journal of natural products, Apr, Volume: 57, Issue:4
Tyrosinase inhibitors from Anacardium occidentale fruits.
AID332458Inhibition of mushroom tyrosinase assessed as oxidation of L-DOPA preincubated for 5 mins before L-DOPA addition1994Journal of natural products, Apr, Volume: 57, Issue:4
Tyrosinase inhibitors from Anacardium occidentale fruits.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.53 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
salicylic acid
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).		1.9810monohydroxybenzoic acidalgal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite
kojic acid
[no description available]		2.1104-pyranones;
enol;
primary alcohol		Aspergillus metabolite;
EC 1.10.3.1 (catechol oxidase) inhibitor;
EC 1.10.3.2 (laccase) inhibitor;
EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor;
EC 1.14.18.1 (tyrosinase) inhibitor;
EC 1.4.3.3 (D-amino-acid oxidase) inhibitor;
NF-kappaB inhibitor;
skin lightening agent
resorcinol
resorcinol: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7951. resorcinol : A benzenediol that is benzene dihydroxylated at positions 1 and 3.		1.9810benzenediol;
phenolic donor;
resorcinols		erythropoietin inhibitor;
sensitiser
3-pentadecylphenol
3-pentadecylphenol: structure in first source		1.9810phenols
adipostatin a
adipostatin A: allergen from cashew nut shell oil; as adipostatin found as inhibitor of glycerol-3-phosphate dehydrogenase from Streptomyces; Also found in bees; do not confuse with cardol, RN 57486-25-6, MF unknown;. cardol : Resorcinol substituted at position 5 by a pentadecyl chain.		1.98105-alkylresorcinolEC 1.1.5.3 (glycerol-3-phosphate dehydrogenase) inhibitor
arbutin
hydroquinone O-beta-D-glucopyranoside : A monosaccharide derivative that is hydroquinone attached to a beta-D-glucopyranosyl residue at position 4 via a glycosidic linkage.		1.9810beta-D-glucoside;
monosaccharide derivative		Escherichia coli metabolite;
plant metabolite
bilobol
bilobol: structure given in first source; RN given refers to (Z)-isomer; RN for cpd without isomeric designation not avail 6/90		1.98105-alkenylresorcinol
ginkgolic acid
[no description available]		1.9810hydroxybenzoic acid
2-hydroxy-6-[(8Z,11Z)-pentadeca-8,11,14-trien-1-yl]benzoic acid
[no description available]		1.9810hydroxybenzoic acid
cardanol
cardanol: from pink pepper; phenol with hydrocarbon side chain which can vary in length & unsaturation		1.9810phenols
ConditionIndicatedRelationship StrengthStudiesTrials
B16 Melanoma
[description not available]		02.110
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510